Holen Sie sich die Stockscreener-App
27.19
0.30%
0.08
Handel nachbörslich:
27.18
-0.01
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$27.11
Offen:
$27.18
24-Stunden-Volumen:
28.75M
Relative Volume:
0.66
Marktkapitalisierung:
$154.67B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
20.06
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
-1.02%
1M Leistung:
+2.29%
6M Leistung:
+11.48%
1J Leistung:
+21.17%
1-Tages-Spanne:
$26.97
$27.36
1-Wochen-Bereich:
$26.68
$27.57
52-Wochen-Spanne:
$21.87
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.19 | 154.21B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
905.03 | 824.12B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.65 | 578.31B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.42 | 371.90B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.21 | 316.96B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.90 | 296.29B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed - Pfizer
Pfizer Inc. stock (US7170811035): Is its wide moat strong enough to unlock new upside? - AD HOC NEWS
UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target - Insider Monkey
Pfizer is Latest Target of FDA's Crackdown on Direct-to-Consumer, Social Media Ads - Law.com
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
Former Pfizer exec estimates 20,000 to 60,000 deaths from COVID shot in Germany - Todayville
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results - qz.com
Earnings Preview: What to Expect From Pfizer’s Report - Barchart.com
Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends - The Motley Fool
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE) - The Globe and Mail
Wells Fargo Releases a Hold Rating on Pfizer (PFE) - The Globe and Mail
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Pfizer, DoHDA talks stall as PBS listing times blow out to almost two years - Health Services Daily
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Pfizer Options Spot-On: On April 13th, 179.18K Contracts Were Traded, With 2.52 Million Open Interest - Moomoo
UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating - marketscreener.com
FDA flags Facebook ads for Pfizer’s cancer drug as misleading - Medical Marketing and Media
UBS Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $27 - Moomoo
Guggenheim reiterates Buy on Pfizer stock ahead of earnings - Investing.com
Guggenheim reiterates Buy on Pfizer stock ahead of earnings By Investing.com - Investing.com Australia
Trellus Health signs renewal of licensing deal with Pfizer - London South East
BMO Capital Adjusts Price Target on Pfizer to $34 From $30, Maintains Outperform Rating - marketscreener.com
Trellus Health shares jump 39% on Pfizer deal renewal - Proactive Investors
Healthcare Stocks: J&J & Pfizer 2026 Outlook Amid Tech ShiftsNews and Statistics - IndexBox
BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27 - Yahoo Finance
Better Buy Right Now: Johnson & Johnson Vs. Pfizer - The Globe and Mail
Pfizer Inc. Trade Ideas — BSESOF:PFE - TradingView — Track All Markets
Pfizer Inc (PFE) Stock Price Quote Today & Current Price Chart - Capital.com
Pfizer’s China Biotech Push Adds New Angle To PFE Valuation Story - Yahoo Finance
Pfizer Options Spot-On: On April 10th, 104.09K Contracts Were Traded, With 2.48 Million Open Interest - Moomoo
Pfizer (PFE) Faces FDA Scrutiny Over Misleading Adcetris Ads - GuruFocus
How Investors Are Reacting To Pfizer (PFE) As RBC Flags Pressure On Key Drug Franchise - simplywall.st
Pfizer (NYSE: PFE) SVP discloses stock and appreciation right holdings - Stock Titan
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $28 - Moomoo
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30 - Moomoo
PFIZER INC : Gets a Neutral rating from JP Morgan - marketscreener.com
Hemophilia B Pipeline 2026 Report Highlights Next-Gen Gene Therapies, FDA Advances, and Clinical Momentum Across Novo Nordisk, Pfizer, Sanofi & Emerging Biotechs | DelveInsight - Barchart
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders - The National Law Review
Pfizer (PFE) Analyst Rating Update: Target Price Lowered to $26 - GuruFocus
Pfizer Invites Shareholders to Virtual 2026 Annual Meeting - National Today
BofA Adjusts Price Target on Pfizer to $26 From $27, Maintains Neutral Rating - marketscreener.com
Pfizer shareholders can vote online at April 23 annual meeting - Stock Titan
BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer - The Manila Times
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump - Yahoo Finance
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause - simplywall.st
Pfizer Inc Storebrand Conference: Invest in the Future Call Transcript - GuruFocus
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pfizer Inc-Aktie (PFE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.51%
3.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):